ScreenerHero

BDTX Black Diamond Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · blackdiamondtherapeutics.com
1.830USD+1.67%Mkt Cap: 105.14M $P/E: —

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is s…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap105.14M USD
Enterprise Value9.88M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)22.37M USD
Revenue/Share0.00 USD
Last Price1.830 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.80
PEG—
EV/EBITDA-0.22
EV/Revenue—
P/SInfinity
P/B1.08
EPS (TTM)-0.69
EPS (Forward)-1.00
52W Range
1.6007% of range4.940
52W High4.940 USD
52W Low1.600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin31.95%
ROE19.93%
ROA15.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF29.61M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-22.42%
Net Debt-93.54M USD
Net Debt/EBITDA2.11
Balance Sheet
Debt/Equity0.17
Current Ratio7.28
Quick Ratio6.97
Book Value/Sh1.67 USD
Cash/Share1.92 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.00 USD
Upside (mean)+446.4%
Target Range8.000 USD – 14.00 USD
8.000+446.4% to mean14.00
# Analysts7
Ownership
Shares Out.57.45M
Float52.51M
Insiders0.66%
Institutions72.58%
Short Interest
Short Ratio9.5d
Short % Float12.88%
Short % Out.8.96%
Shares Short5.15M
Short (prev mo.)6.19M
Technical
SMA 501.983 (-7.7%)
SMA 2002.266 (-19.2%)
Beta3.33
S&P 52W Chg16.45%
Avg Vol (30d)588.15K
Avg Vol (10d)554.56K
Technical Indicators
RSI (14)41.4
MACD-0.0424
MACD Signal-0.0312
MACD Hist.-0.0113
BB Upper2.096 USD
BB Middle1.931 USD
BB Lower1.767 USD
BB Width17.02%
ATR (14)0.0943 USD
Vol Ratio (20d)0.94x